CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis
Blood · 18.04.2024 · 143 (16) · 1628-1645
DOI: 10.1182/blood.2023021380 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, erschienen am 18.04.2024. Verfasst von Giorgia Renga und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Perugia, Perugia, Italy. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
CPX-351, a liposomal combination of cytarabine plus daunorubicin, has been approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes, because it improves survival and outcome of patients who received hematopoietic stem cell transplant compared with the continuous infusion of cytarabine plus daunorubicin (referred to as “7 + 3” combination). Because gut dysbiosis occurring in patients with AML during induction chemotherapy heavily affects the subsequent phases of therapy, we have assessed whether the superior activity of CPX-351 vs “7 + 3” combination in the real-life setting implicates an action on and by the intestinal microbiota. To this purpose, we have evaluated the impact of CPX-351 and “7 + 3” combination on mucosal barrier function, gut microbial composition and function, and antifungal colonization resistance in preclinical models of intestinal damage in vitro and in vivo and fecal microbiota transplantation. We found that CPX-351, at variance with “7 + 3” combination, protected from gut dysbiosis, mucosal damage, and gut morbidity while increasing antifungal resistance. Mechanistically, the protective effect of CPX-351 occurred through pathways involving both the host and the intestinal microbiota, namely via the activation of the aryl hydrocarbon receptor–interleukin-22 (IL-22)–IL-10 host pathway and the production of immunomodulatory metabolites by anaerobes. This study reveals how the gut microbiota may contribute to the good safety profile, with a low infection-related mortality, of CPX-351 and highlights how a better understanding of the host-microbiota dialogue may contribute to pave the way for precision medicine in AML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, University of Perugia, Perugia, Italy.
- Department of Pharmaceutical Science, University of Perugia, Perugia, Italy.
- Department of Health Sciences, University of Florence, Florence, Italy.
- Department of Biology, University of Rome "Tor Vergata," Rome, Italy.
- San Raffaele Sulmona, Sulmona, Italy.
- Division of Hematology, Policlinico Gemelli, Università Cattolica Sacro Cuore, Rome, Italy.
ORCID-Profile: Claudia Stincardini, Matteo Puccetti, Giuseppe Pieraccini, Claudia Di Serio, Noemi Poerio, Vasileios Oikonomou, Paolo Mosci, Livio Pagano
Zitieren
APA
Renga, G., Nunzi, E., Stincardini, C., Pariano, M., Puccetti, M., Pieraccini, G., Di Serio, C., Fraziano, M., Poerio, N., Oikonomou, V., Mosci, P., Garaci, E., Fianchi, L., Pagano, L., & Romani, L. (2024). CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis. Blood, 143(16), 1628-1645. https://doi.org/10.1182/blood.2023021380
Vancouver
Renga G, Nunzi E, Stincardini C, Pariano M, Puccetti M, Pieraccini G, et al. CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis. Blood. 2024;143(16):1628-1645. doi:10.1182/blood.2023021380
BibTeX
@article{Renga2024,
author = {Renga, Giorgia and Nunzi, Emilia and Stincardini, Claudia and Pariano, Marilena and Puccetti, Matteo and Pieraccini, Giuseppe and Di Serio, Claudia and Fraziano, Maurizio and Poerio, Noemi and Oikonomou, Vasileios and Mosci, Paolo and Garaci, Enrico and Fianchi, Luana and Pagano, Livio and Romani, Luigina},
title = {CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis},
journal = {Blood},
year = {2024},
volume = {143},
number = {16},
pages = {1628--1645},
doi = {10.1182/blood.2023021380}
}
EUVIMED